论文部分内容阅读
目的:探讨包含CD56的白血病相关抗原表型(leukem ia-assoc iated antigen phenotype,LAIP)检测在急性髓系白血病(acute myelocytic leukem ia,AML)-M4/M5中的临床意义。方法:采用多色流式细胞术对26例AML-M4/M5患者的免疫分型和微小残留病变(m icroresidual d isease,MRD)进行检测。结果:AML-M4/M5髓系相关标记以CyMPO(100%)表达最高,其次为CD13(92.31%)、CD33(76.92%)。CD56阳性占了26.92%。CD56阳性组的无病生存(d is-ease-free survival,DFS)率为42.9%,低于CD56阴性组的84.2%,差别具有统计学意义(P<0.05)。包含CD56的LAIP与复发情况的Kappa一致性检验值为0.30,不包含CD56的LAIP与复发情况的Kappa一致性检验值为0.16。结论:CD56对AML-M4/M5的预后判断有重要意义。包含CD56的LAIP更有助于检出AML-M4/M5的MRD。
Objective: To investigate the clinical significance of CD56-containing leukemia-associated iated antigen phenotype (LAIP) detection in acute myelocytic leukemia (AML) -M4 / M5. Methods: Immunofluorescence and m icroresidual d isease (MRD) were detected in 26 patients with AML-M4 / M5 by multicolor flow cytometry. Results: The myeloid-associated markers of AML-M4 / M5 had the highest expression of CyMPO (100%), followed by CD13 (92.31%) and CD33 (76.92%). CD56 positive accounted for 26.92%. The disease-free survival (DFS) rate of CD56 positive patients was 42.9%, which was lower than that of CD56 negative patients (84.2%), the difference was statistically significant (P <0.05). The Kappa consistency test for LAIP with recurrence of CD56 was 0.30, and the Kappa consistency test for LAIP with no recurrence for CD56 was 0.16. Conclusion: CD56 plays an important role in the prognosis of AML-M4 / M5. The LAIP containing CD56 is more useful for detecting MRDs of AML-M4 / M5.